Biocryst Pharmaceuticals Inc [BCRX] stock prices are up 6.07% to $6.81 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BCRX shares have lost -6.46% over the last week, with a monthly amount drifted -12.13%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Evercore ISI downgraded its rating to In-line on October 01, 2025, and kept the price target unchanged to $8. On April 29, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $20 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $15 on February 25, 2025. RBC Capital Mkts upgraded its rating to Outperform for this stock on September 18, 2023, and upped its price target to $10. In a note dated August 04, 2023, Jefferies upgraded a Buy rating on this stock but restated the target price of $11.
The stock price of Biocryst Pharmaceuticals Inc [BCRX] has been fluctuating between $6.00 and $11.31 over the past year. Currently, Wall Street analysts expect the stock to reach $12.67 within the next 12 months. Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] shares were valued at $6.81 at the most recent close of the market. An investor can expect a potential return of 86.05% based on the average BCRX price forecast.
Analyzing the BCRX fundamentals
The Biocryst Pharmaceuticals Inc [NASDAQ:BCRX] reported sales of 557.51M for trailing twelve months, representing a surge of 49.41%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at 0.1%, Pretax Profit Margin comes in at -0.06%, and Net Profit Margin reading is -0.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is 0.08 and Total Capital is 0.19. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.75.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Biocryst Pharmaceuticals Inc [NASDAQ:BCRX]’s Current Ratio is 2.25. Further, the Quick Ratio stands at 2.22, while the Cash Ratio is 0.5. Considering the valuation of this stock, the price to sales ratio is 2.56.
Transactions by insiders
Recent insider trading involved HEGGIE THERESA, Director, that happened on Aug 13 ’25 when 70000.0 shares were sold. Director, HEGGIE THERESA completed a deal on Aug 13 ’25 to buy 70000.0 shares. Meanwhile, Director Hutson Nancy J sold 7000.0 shares on Dec 13 ’24.
